Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-3070

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 71335-3070). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C:\users\ra\desktop\1.jpg (5a5eca60 Figure 01)

A line graph depicting the percentage of patients achieving systolic blood pressure (SBP) below 140 mmHg versus baseline SBP (140 to 180 mmHg). Four treatment groups are shown: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, with distinct markers representing each group.*

FDA Label Image

C:\users\ra\desktop\2.jpg (5a5eca60 Figure 02)

A line graph showing the percentage of diastolic blood pressure (DBP) measurements below 90 mmHg across a range of baseline DBP values from 90 to 110 mmHg. The graph compares four groups: valsartan-HCTZ 320/25 mg, valsartan 320 mg, hydrochlorothiazide 25 mg, and placebo, illustrating the relative effectiveness of each treatment in lowering DBP.*

FDA Label Image

C:\users\ra\desktop\3.jpg (5a5eca60 Figure 03)

This figure is a line graph comparing the percentage of patients with systolic blood pressure (SBP) under 130 mmHg across different baseline SBP values from 140 to 180 mmHg. The graph includes four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, represented by distinct markers. It shows relative efficacy in blood pressure reduction for each treatment group.*

FDA Label Image

C:\users\ra\desktop\4.jpg (5a5eca60 Figure 04)

A line chart showing the percentage of patients with diastolic blood pressure (DBP) below 80 mmHg plotted against baseline DBP (mmHg). The chart compares four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, each represented by different symbols in the legend.*

FDA Label Image

C:\users\ra\desktop\5.jpg (5a5eca60 Figure 05)

Chemical structure diagram illustrating the molecular composition of valsartan, an active ingredient in the drug product valsartan and hydrochlorothiazide tablets, film coated.*

FDA Label Image

C:\users\ra\desktop\6.jpg (5a5eca60 Figure 06)

Chemical structure diagram showing the molecular structure of the active ingredient, likely related to valsartan and hydrochlorothiazide tablets as per the product data.*

FDA Label Image

Label (Lbl713353070)

Label for Valsartan and Hydrochlorothiazide tablets USP, 320 mg/12.5 mg strength. It shows the product is repackaged by Bryant Ranch Prepack, Inc. in Burbank, CA and manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. The label includes storage instructions, dosage guidance via QR code, and package size of 30 tablets. Barcodes and NDC 71335-3070-1 are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.